学术报告题目：The application of genome-wide CRISPR knockout screens in translational research on hepatocellular carcinoma
Dr Wang Yu graduated with BSc (Hons) in biological sciences from Nanyang Technological University in 2006 and PhD in biomedical sciences from National University of Singapore. He is currently working as a Senior Research Fellow at the National Cancer Centre Singapore. His research lies in understanding and improving the treatment of hepatocellular carcinoma. He has published more than 18 peer-reviewed articles on HCC and received 3 Singapore national level grants as principle investigator.
Liver cancer is the 6th most common cancer worldwide and hepatocellular carcinoma (HCC) accounts for more than 85% of all primary liver cancer cases. Chronic hepatitis B virus infection is the major etiologic factor associated with HCC in Asia. Currently, serum alpha-fetoprotein level and oncologic imaging methods such as ultrasound, CT or MRI are the standard tools for HCC surveillance. HCC is also the 2nd leading cause of cancer related death globally, killing over 600,000 patients each year. Surgical resection and liver transplantation are the most treatment modality that consistently conveys survival advantage to HCC patients while conventional radio-, chemo- and hormonal therapies are largely infective. Therefore, HCC’s high mortality is a combination of high incidence, inadequate early detection methods and very limited treatment options. In this talk, I will share our experience in using genome-wide CRISPR knockout screens as tools to identify novel therapeutic targets and to enable personalized treatment in HCC.